董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert More | 男 | Chairman of the Board, Independent Director | 58 | 23.27万美元 | 412.79 | 2026-05-28 |
| Habib J. Dable | 男 | Independent Director | 56 | 未披露 | 未持股 | 2026-05-28 |
| Adele M. Gulfo | 女 | Independent Director | 63 | 55.37万美元 | 0.81 | 2026-05-28 |
| Melissa McCracken | 女 | Independent Director | 39 | 未披露 | 未持股 | 2026-05-28 |
| Jake Simson | 男 | Independent Director | 40 | 20.35万美元 | 4.76 | 2026-05-28 |
| Rehan Verjee | 男 | Independent Director | 46 | 20.56万美元 | 11.51 | 2026-05-28 |
| Todd Harris | -- | Chief Executive Officer,Director and President | 47 | 556.70万美元 | 253.06 | 2026-05-28 |
| Susan Moran | 女 | Independent Director | 57 | 20.33万美元 | 1.24 | 2026-05-28 |
| S. Michael Rothenberg | 男 | Independent Director | 56 | 19.25万美元 | 1.24 | 2026-05-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Todd Harris | -- | Chief Executive Officer,Director and President | 47 | 556.70万美元 | 253.06 | 2026-05-28 |
| Douglas Warner | 男 | Chief Medical Officer | 54 | 237.22万美元 | 未持股 | 2026-05-28 |
| Bhavesh Ashar | 男 | Chief Operating Officer | 57 | 468.53万美元 | 未持股 | 2026-05-28 |
| Alan Fuhrman | 男 | Chief Financial Officer | 70 | 未披露 | 未持股 | 2026-05-28 |
董事简历
中英对照 | 中文 | 英文- Robert More
-
Robert More自2016年9月以来一直担任我们的董事会成员。自2016年10月以来，More先生一直担任风险投资公司Alta Partners的董事总经理。从2013年7月到2015年5月，More先生担任比尔与梅琳达·盖茨基金会（Bill&Melinda Gates Foundation）的高级顾问，并领导其全球健康创业计划。2008年9月至2013年6月和1996年6月至2008年7月，他分别担任风险投资公司Frazier梦百合Ventures和Domain Associates的普通合伙人。More先生目前担任SiennaBiopharmaceuticals，Inc.公司（一家公共制药公司）的董事会成员。他目前也任职于以下私人公司的董事会:生物技术公司AffiniVax，Inc.、生物技术公司eGenesis、生物技术公司Qihan Biotech、生物技术公司Sirenas，LLC、生物技术公司Tyra Biosciences，Inc.，并担任Liquiglide，Inc.（生物技术公司）的顾问。莫尔曾担任以下上市公司的董事会成员:生物制药公司Achaogen，Inc.、医疗设备公司Carticept Medical，Inc.、医疗设备公司Cartiva、制药公司Neothetics Inc.、医疗技术公司Glaukos Corporation和IntraLase Corp.，2007年被Advanced Medical Optics收购的医疗器械公司。他此前也曾任职于以下生命科学公司的董事会:ESP Pharma，Inc.、Proxima Therapeutics，Inc.、Novacardia，Inc.、Esprit Pharma，Inc.和Oceana Therapeutics，Inc.。More先生是考夫曼研究员计划（Kauffman Fellows Program）的董事会创始成员，之前曾在One Revolution和Foundation for Innovative New Diagnostics Find的董事会任职。More先生目前在生物技术创新组织（BIO）的理事会之一任职。他在Middlebury College获得生物学学士学位，在University of Virginia的Darden工商管理学院获得工商管理硕士学位。
Robert More,Managing Director, Alta Partners (2016 – 2025),Senior Advisor, Bill & Melinda Gates Foundation (2013– 2015),General Partner, Frazier Healthcare Ventures (2008 – 2013),General Partner, Domain Associates (1996 – 2008),B.S., Biology, Middlebury College,MBA, Darden School of Business Administration at the University of Virginia. - Robert More自2016年9月以来一直担任我们的董事会成员。自2016年10月以来，More先生一直担任风险投资公司Alta Partners的董事总经理。从2013年7月到2015年5月，More先生担任比尔与梅琳达·盖茨基金会（Bill&Melinda Gates Foundation）的高级顾问，并领导其全球健康创业计划。2008年9月至2013年6月和1996年6月至2008年7月，他分别担任风险投资公司Frazier梦百合Ventures和Domain Associates的普通合伙人。More先生目前担任SiennaBiopharmaceuticals，Inc.公司（一家公共制药公司）的董事会成员。他目前也任职于以下私人公司的董事会:生物技术公司AffiniVax，Inc.、生物技术公司eGenesis、生物技术公司Qihan Biotech、生物技术公司Sirenas，LLC、生物技术公司Tyra Biosciences，Inc.，并担任Liquiglide，Inc.（生物技术公司）的顾问。莫尔曾担任以下上市公司的董事会成员:生物制药公司Achaogen，Inc.、医疗设备公司Carticept Medical，Inc.、医疗设备公司Cartiva、制药公司Neothetics Inc.、医疗技术公司Glaukos Corporation和IntraLase Corp.，2007年被Advanced Medical Optics收购的医疗器械公司。他此前也曾任职于以下生命科学公司的董事会:ESP Pharma，Inc.、Proxima Therapeutics，Inc.、Novacardia，Inc.、Esprit Pharma，Inc.和Oceana Therapeutics，Inc.。More先生是考夫曼研究员计划（Kauffman Fellows Program）的董事会创始成员，之前曾在One Revolution和Foundation for Innovative New Diagnostics Find的董事会任职。More先生目前在生物技术创新组织（BIO）的理事会之一任职。他在Middlebury College获得生物学学士学位，在University of Virginia的Darden工商管理学院获得工商管理硕士学位。
- Robert More,Managing Director, Alta Partners (2016 – 2025),Senior Advisor, Bill & Melinda Gates Foundation (2013– 2015),General Partner, Frazier Healthcare Ventures (2008 – 2013),General Partner, Domain Associates (1996 – 2008),B.S., Biology, Middlebury College,MBA, Darden School of Business Administration at the University of Virginia.
- Habib J. Dable
-
HabibJ.Dable从2018年9月起担任二等兵米伦多（Millendo&8217；）的董事会成员，直到合并完成，他被任命为我们的董事会成员。Dable先生自2016年12月起担任生物制药公司Acceleron PharmaInc.（Nasdaq:XLRN）的首席执行官兼总裁兼董事会成员。在此之前，Dable先生于1994年开始在拜耳公司（Bayer AG）担任越来越重要的职务，最近于2015年10月至2016年12月担任美国拜耳制药总裁。2013年至2015年，Dable先生担任拜耳梦百合Pharmaceuticals的执行Vice President兼专业药物全球主管，2010年至2012年，他担任Eylea眼科和全球启动团队主管的Vice President。Dable先生在加拿大新不伦瑞克大学（University of New Brunswick）获得工商管理学士学位和硕士学位。
Habib J. Dable has served as a member of Tyra Biosciences, Inc.'s Board since April 2026. Mr. Dable has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022. Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021. Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable has served as a member of the board of directors of Spyglass Pharma, Inc. since February 2026, Relay Therapeutics, Inc. since November 2025, Day One Biopharmaceuticals, Inc. since January 2024, and PepGen Inc. since September 2022, and he previously served as a member of the board of directors of Millendo Therapeutics, Inc. from September 2018 until January 2021, Blueprint Medicines Corporation (which was subsequently acquired by Sanofi S.A.) from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. (which was subsequently acquired by Ipsen Biopharmaceuticals, Inc.) from August 2022 to March 2023. Mr. Dable holds a bachelor's degree in business administration and an MBA, each from the University of New Brunswick in Canada. Tyra Biosciences, Inc. - HabibJ.Dable从2018年9月起担任二等兵米伦多（Millendo&8217；）的董事会成员，直到合并完成，他被任命为我们的董事会成员。Dable先生自2016年12月起担任生物制药公司Acceleron PharmaInc.（Nasdaq:XLRN）的首席执行官兼总裁兼董事会成员。在此之前，Dable先生于1994年开始在拜耳公司（Bayer AG）担任越来越重要的职务，最近于2015年10月至2016年12月担任美国拜耳制药总裁。2013年至2015年，Dable先生担任拜耳梦百合Pharmaceuticals的执行Vice President兼专业药物全球主管，2010年至2012年，他担任Eylea眼科和全球启动团队主管的Vice President。Dable先生在加拿大新不伦瑞克大学（University of New Brunswick）获得工商管理学士学位和硕士学位。
- Habib J. Dable has served as a member of Tyra Biosciences, Inc.'s Board since April 2026. Mr. Dable has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022. Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021. Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable has served as a member of the board of directors of Spyglass Pharma, Inc. since February 2026, Relay Therapeutics, Inc. since November 2025, Day One Biopharmaceuticals, Inc. since January 2024, and PepGen Inc. since September 2022, and he previously served as a member of the board of directors of Millendo Therapeutics, Inc. from September 2018 until January 2021, Blueprint Medicines Corporation (which was subsequently acquired by Sanofi S.A.) from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. (which was subsequently acquired by Ipsen Biopharmaceuticals, Inc.) from August 2022 to March 2023. Mr. Dable holds a bachelor's degree in business administration and an MBA, each from the University of New Brunswick in Canada. Tyra Biosciences, Inc.
- Adele M. Gulfo
-
Adele M. Gulfo，自2019年12月起担任Sumitovant Biopharma的首席商业和商业发展官。Sumitovant Biopharma是Sumitomo Dainippon Pharma Co.，Ltd.的全资子公司，运营着5家生物制药公司，于2019年12月从Roivant Sciences Ltd.收购。从2018年5月到2019年12月，她担任Roivant Sciences的商业开发主管。在2018年5月加入Roivant Sciences之前，她曾担任Mylan N.V。的执行副总裁和全球商业发展主管（2014年1月至2018年1月）。加入Mylan之前，Gulfo女士在Pfizer Inc.任职5年，担任多个执行职位，包括美国初级保健总裁和总经理。她还跑商业运作和管理市场组织在辉瑞生物制药业务在美国加入辉瑞之前，她担任几个高管职位在阿斯利康制药和Parke-Davis华纳兰波特后来分工与辉瑞公司合并，作为高级主管，为该公司的心血管市场营销，她推出了立普妥，最畅销的药品。她持有Seton Hall University的生物学学士学位和Fairleigh Dickinson University的市场营销工商管理硕士学位。
Adele M. Gulfo served as the Chief Executive Officer, Biopharma Commercial Unit for Sumitomo Pharma America from July 2023 to September 2024. She served as Chief Biness and Commercial Development Officer at Sumitovant Biopharma from December 2019 to July 2023 when Sumitovant and related entities merged into Sumitomo Pharma America. Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V. (now Viatris) from January 2014 to January 2018. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer's biopharmaceutical biness in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke Davis division of Warner Lambert (which later merged with Pfizer), and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best selling pharmaceutical product. She is a member of the Innovation Growth Board at Mass General Brigham, the largest hospital based research enterprise in the United States, and serves as a director of Battelle Memorial Institute, an independent, non profit applied science and technology research organization.Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an M.B.A. in Marketing from Fairleigh Dickinson University. - Adele M. Gulfo，自2019年12月起担任Sumitovant Biopharma的首席商业和商业发展官。Sumitovant Biopharma是Sumitomo Dainippon Pharma Co.，Ltd.的全资子公司，运营着5家生物制药公司，于2019年12月从Roivant Sciences Ltd.收购。从2018年5月到2019年12月，她担任Roivant Sciences的商业开发主管。在2018年5月加入Roivant Sciences之前，她曾担任Mylan N.V。的执行副总裁和全球商业发展主管（2014年1月至2018年1月）。加入Mylan之前，Gulfo女士在Pfizer Inc.任职5年，担任多个执行职位，包括美国初级保健总裁和总经理。她还跑商业运作和管理市场组织在辉瑞生物制药业务在美国加入辉瑞之前，她担任几个高管职位在阿斯利康制药和Parke-Davis华纳兰波特后来分工与辉瑞公司合并，作为高级主管，为该公司的心血管市场营销，她推出了立普妥，最畅销的药品。她持有Seton Hall University的生物学学士学位和Fairleigh Dickinson University的市场营销工商管理硕士学位。
- Adele M. Gulfo served as the Chief Executive Officer, Biopharma Commercial Unit for Sumitomo Pharma America from July 2023 to September 2024. She served as Chief Biness and Commercial Development Officer at Sumitovant Biopharma from December 2019 to July 2023 when Sumitovant and related entities merged into Sumitomo Pharma America. Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V. (now Viatris) from January 2014 to January 2018. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer's biopharmaceutical biness in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke Davis division of Warner Lambert (which later merged with Pfizer), and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best selling pharmaceutical product. She is a member of the Innovation Growth Board at Mass General Brigham, the largest hospital based research enterprise in the United States, and serves as a director of Battelle Memorial Institute, an independent, non profit applied science and technology research organization.Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an M.B.A. in Marketing from Fairleigh Dickinson University.
- Melissa McCracken
-
Melissa McCracken自2021年3月起担任我们的董事会成员。自2019年9月以来，McCracken博士一直担任Nextech Invest Ltd.的高级合伙人，目前担任负责人，Nextech Invest Ltd.是一家专注于癌症治疗的风险投资公司，几乎完全专注于精密治疗。在加入Nextech Invest Ltd.之前，从2017年3月到2019年8月，McCracken博士是Third Rock Ventures，LLC的合伙人和高级合伙人，该公司是一家风险投资公司，她专注于科学尽职调查，合伙开发和肿瘤和免疫学的新公司组建。在Third Rock Ventures，McCracken博士帮助建立和推出了Celsius Therapeutics Inc.，这是一家专注于从2018年3月到2019年3月发现肿瘤和自身免疫精密疗法的公司。McCracken博士目前担任Iconovir Bio，Inc.的董事会观察员，此前曾担任Imaginab Inc.的董事会成员和SilverbackTherapeutics，Inc.的董事会观察员McCracken博士拥有加州大学戴维斯分校生物化学和分子生物学学士学位，加州大学洛杉矶分校药理学博士学位。
Melissa McCracken,has served as a member of Tyra Biosciences, Inc. Board since March 2021. Since September 2019, Dr. McCracken has served as a principal and currently as a partner at Nextech Invest Ltd., a venture capital firm focused on precision therapeutics. Prior to Nextech, Dr. McCracken was an associate and then senior associate at Third Rock Ventures, LLC from February 2017 until August 2019, a venture capital firm where she focused on scientific due diligence, partnership development and new company formation in oncology and immunology. At Third Rock Ventures, Dr. McCracken helped build and launch Celsius Therapeutics Inc., a company focused on discovering precision therapeutics for oncology and autoimmune diseases and worked with the founding team from March 2018 to March 2019. Dr. McCracken currently serves as a board member of A2 Biotherapeutics, Inc., AIRNA Corporation, Alterome Therapeutics, Inc., Ambagon Therapeutics, Inc., Alpha-9 Oncology, Be Biopharma Inc., K36 Therapeutics, Inc. and was previously a board member of ImaginAB Inc. and board observer of ProfoundBio, Inc., Silverback Therapeutics, Inc. and IconOvir Bio, Inc. Dr. McCracken holds a Bachelor of Science in Biochemistry and Molecular Biology from the University of California, Davis and a Ph.D. in Pharmacology from the University of California, Los Angeles. - Melissa McCracken自2021年3月起担任我们的董事会成员。自2019年9月以来，McCracken博士一直担任Nextech Invest Ltd.的高级合伙人，目前担任负责人，Nextech Invest Ltd.是一家专注于癌症治疗的风险投资公司，几乎完全专注于精密治疗。在加入Nextech Invest Ltd.之前，从2017年3月到2019年8月，McCracken博士是Third Rock Ventures，LLC的合伙人和高级合伙人，该公司是一家风险投资公司，她专注于科学尽职调查，合伙开发和肿瘤和免疫学的新公司组建。在Third Rock Ventures，McCracken博士帮助建立和推出了Celsius Therapeutics Inc.，这是一家专注于从2018年3月到2019年3月发现肿瘤和自身免疫精密疗法的公司。McCracken博士目前担任Iconovir Bio，Inc.的董事会观察员，此前曾担任Imaginab Inc.的董事会成员和SilverbackTherapeutics，Inc.的董事会观察员McCracken博士拥有加州大学戴维斯分校生物化学和分子生物学学士学位，加州大学洛杉矶分校药理学博士学位。
- Melissa McCracken,has served as a member of Tyra Biosciences, Inc. Board since March 2021. Since September 2019, Dr. McCracken has served as a principal and currently as a partner at Nextech Invest Ltd., a venture capital firm focused on precision therapeutics. Prior to Nextech, Dr. McCracken was an associate and then senior associate at Third Rock Ventures, LLC from February 2017 until August 2019, a venture capital firm where she focused on scientific due diligence, partnership development and new company formation in oncology and immunology. At Third Rock Ventures, Dr. McCracken helped build and launch Celsius Therapeutics Inc., a company focused on discovering precision therapeutics for oncology and autoimmune diseases and worked with the founding team from March 2018 to March 2019. Dr. McCracken currently serves as a board member of A2 Biotherapeutics, Inc., AIRNA Corporation, Alterome Therapeutics, Inc., Ambagon Therapeutics, Inc., Alpha-9 Oncology, Be Biopharma Inc., K36 Therapeutics, Inc. and was previously a board member of ImaginAB Inc. and board observer of ProfoundBio, Inc., Silverback Therapeutics, Inc. and IconOvir Bio, Inc. Dr. McCracken holds a Bachelor of Science in Biochemistry and Molecular Biology from the University of California, Davis and a Ph.D. in Pharmacology from the University of California, Los Angeles.
- Jake Simson
-
Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
Jake Simson has served as a member of Parabilis Medicines, Inc.'s board of directors since January 2026. Since December 2020, Dr. Simson has served as a Partner of RA Capital Management, L.P., a life sciences investment advisor. Dr. Simson previously served as an associate, analyst and principal at RA Capital Management, L.P. from July 2013 to December 2020. Dr. Simson serves as a member of the board of directors of Tyra Biosciences Inc, a public biotechnology company (NASDAQ GS: TYRA), Janux Therapeutics, Inc, a public biopharmaceutical company (NASDAQ: JANX), Septerna, Inc., a public biotechnology company (NASDAQ: SEPN), and Bicara Therapeutics Inc., a public biotechnology company (NASDAQ: BCAX). Dr. Simson also served on the board of directors of DICE Therapeutics, Inc., a biotechnology company (NASDAQ: DICE), from December 2020 until it was acquired by Eli Lilly and Company (NYSE: LLY) in August 2023. Dr. Simson also serves on the boards of directors of various private companies. Dr. Simson received his Ph.D. in Biomedical Engineering from Johns Hopkins University and his S.B. in Materials Science and Engineering from Massachusetts Institute of Technology. - Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
- Jake Simson has served as a member of Parabilis Medicines, Inc.'s board of directors since January 2026. Since December 2020, Dr. Simson has served as a Partner of RA Capital Management, L.P., a life sciences investment advisor. Dr. Simson previously served as an associate, analyst and principal at RA Capital Management, L.P. from July 2013 to December 2020. Dr. Simson serves as a member of the board of directors of Tyra Biosciences Inc, a public biotechnology company (NASDAQ GS: TYRA), Janux Therapeutics, Inc, a public biopharmaceutical company (NASDAQ: JANX), Septerna, Inc., a public biotechnology company (NASDAQ: SEPN), and Bicara Therapeutics Inc., a public biotechnology company (NASDAQ: BCAX). Dr. Simson also served on the board of directors of DICE Therapeutics, Inc., a biotechnology company (NASDAQ: DICE), from December 2020 until it was acquired by Eli Lilly and Company (NYSE: LLY) in August 2023. Dr. Simson also serves on the boards of directors of various private companies. Dr. Simson received his Ph.D. in Biomedical Engineering from Johns Hopkins University and his S.B. in Materials Science and Engineering from Massachusetts Institute of Technology.
- Rehan Verjee
-
Rehan Verjee自2021年6月起担任我们的董事会成员。从2018年9月到2021年3月，Verjee先生担任德国达姆施塔特Merck KGaA的EMD Serono总裁兼创新药物专营权全球主管，在那里他领导北美生物制药业务遍及美国和加拿大，以及领导全球肿瘤和神经学和免疫学专业药物专营权的Merck KGaA的医疗保健业务，达姆施塔特，德国。在此之前，Verjee先生自2015年10月起担任执行副总裁、首席营销和战略官，领导肿瘤、神经学和免疫学以及不孕不育的全球专营权，此外还负责全球业务开发、市场准入、战略和投资组合管理，营销业务和医疗设备及服务股。在此之前，他作为EMD Serono Canada Inc.的常务董事领导加拿大业务。Verjee先生目前是马萨诸塞州生物技术委员会的董事会成员。Verjee先生拥有英国牛津大学分子和细胞生物化学硕士学位。
Rehan Verjee has served as a member of our board of directors since June 2021. From September 2018 to March 2021 Mr. Verjee has served as President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, where he led the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany. Prior to this role, Mr. Verjee served as Executive Vice President, Chief Marketing and Strategy Officer since October 2015 leading the global franchises of oncology, neurology & immunology, and infertility, in addition to global business development, market access, strategy and portfolio management, marketing operations and the medical device and services unit. Prior to this, he led the Canadian operations as Managing Director of EMD Serono Canada Inc. Mr. Verjee is currently a member of the board of directors of Massachusetts Biotechnology Council. Mr. Verjee holds a Master’s Degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K. - Rehan Verjee自2021年6月起担任我们的董事会成员。从2018年9月到2021年3月，Verjee先生担任德国达姆施塔特Merck KGaA的EMD Serono总裁兼创新药物专营权全球主管，在那里他领导北美生物制药业务遍及美国和加拿大，以及领导全球肿瘤和神经学和免疫学专业药物专营权的Merck KGaA的医疗保健业务，达姆施塔特，德国。在此之前，Verjee先生自2015年10月起担任执行副总裁、首席营销和战略官，领导肿瘤、神经学和免疫学以及不孕不育的全球专营权，此外还负责全球业务开发、市场准入、战略和投资组合管理，营销业务和医疗设备及服务股。在此之前，他作为EMD Serono Canada Inc.的常务董事领导加拿大业务。Verjee先生目前是马萨诸塞州生物技术委员会的董事会成员。Verjee先生拥有英国牛津大学分子和细胞生物化学硕士学位。
- Rehan Verjee has served as a member of our board of directors since June 2021. From September 2018 to March 2021 Mr. Verjee has served as President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, where he led the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany. Prior to this role, Mr. Verjee served as Executive Vice President, Chief Marketing and Strategy Officer since October 2015 leading the global franchises of oncology, neurology & immunology, and infertility, in addition to global business development, market access, strategy and portfolio management, marketing operations and the medical device and services unit. Prior to this, he led the Canadian operations as Managing Director of EMD Serono Canada Inc. Mr. Verjee is currently a member of the board of directors of Massachusetts Biotechnology Council. Mr. Verjee holds a Master’s Degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.
- Todd Harris
-
Todd Harris自2018年11月以来担任我们的总裁，首席执行官和秘书，自2019年2月以来担任我们的财务主管，自2018年8月以来担任我们的董事会成员。在共同创立Tyra之前，Harris博士担任过各种职务，最近担任SiennaBiopharmaceuticals，Inc.的企业发展主管和董事。SNNA，即Sienna，一家临床阶段的生物制药公司，从2016年1月到2018年7月，此前从2013年4月到2016年1月担任Sienna（当时称为Sienna Labs）的创始人、首席执行官和董事。2019年9月，Sienna Biopharmaceuticals根据美国破产法第11章提出自愿申请，允许重组，并于2019年12月停止运营。在Sienna之前，从2008年9月到2012年12月，Harris博士是麦肯锡公司（McKinsey&Company）医疗实践部门的顾问。Harris博士目前是Primune Therapeutics，Inc.的董事会成员，该公司是一家生物制药公司，专注于第二只手——先天免疫系统。Harris博士拥有杨百翰大学电气工程理学学士学位，加州大学圣地亚哥分校生物工程理学硕士学位，麻省理工学院医学工程和医学物理学博士学位。
Todd Harris has served as our President, Chief Executive Officer and Secretary since November 2018 as our Treasurer since February 2019 and as a member of our board of directors since August 2018. Prior to co-founding Tyra, Dr. Harris served in various roles, most recently as Head of Corporate Development and a director at Sienna Biopharmaceuticals, Inc. SNNA, or Sienna, a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and previously as the founder, Chief Executive Officer, and director of Sienna (then called Sienna Labs) from April 2013 to January 2016. In September 2019 Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division from September 2008 to December 2012. Dr. Harris currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Dr. Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology. - Todd Harris自2018年11月以来担任我们的总裁，首席执行官和秘书，自2019年2月以来担任我们的财务主管，自2018年8月以来担任我们的董事会成员。在共同创立Tyra之前，Harris博士担任过各种职务，最近担任SiennaBiopharmaceuticals，Inc.的企业发展主管和董事。SNNA，即Sienna，一家临床阶段的生物制药公司，从2016年1月到2018年7月，此前从2013年4月到2016年1月担任Sienna（当时称为Sienna Labs）的创始人、首席执行官和董事。2019年9月，Sienna Biopharmaceuticals根据美国破产法第11章提出自愿申请，允许重组，并于2019年12月停止运营。在Sienna之前，从2008年9月到2012年12月，Harris博士是麦肯锡公司（McKinsey&Company）医疗实践部门的顾问。Harris博士目前是Primune Therapeutics，Inc.的董事会成员，该公司是一家生物制药公司，专注于第二只手——先天免疫系统。Harris博士拥有杨百翰大学电气工程理学学士学位，加州大学圣地亚哥分校生物工程理学硕士学位，麻省理工学院医学工程和医学物理学博士学位。
- Todd Harris has served as our President, Chief Executive Officer and Secretary since November 2018 as our Treasurer since February 2019 and as a member of our board of directors since August 2018. Prior to co-founding Tyra, Dr. Harris served in various roles, most recently as Head of Corporate Development and a director at Sienna Biopharmaceuticals, Inc. SNNA, or Sienna, a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and previously as the founder, Chief Executive Officer, and director of Sienna (then called Sienna Labs) from April 2013 to January 2016. In September 2019 Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division from September 2008 to December 2012. Dr. Harris currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Dr. Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.
- Susan Moran
-
Susan Moran，自2021年7月起担任Rayzebio，Inc.首席医疗官。此前，莫兰博士曾于2018年3月至2021年6月担任上市生物技术公司BridgeBio Pharma的附属公司QED治疗公司的首席医疗官。在加入QED之前，莫兰博士于2014年至2018年2月在上市生物制药公司Puma Biotechnology, Inc.工作。莫兰博士一直担任高级医学主任，直到2016年12月，她的职位扩大到副总裁兼临床开发主管。在加入彪马之前，莫兰博士曾于2011年至2014年在上市生物制药公司Takeda Oncology担任医学总监，并于2007年至2011年在上市生物技术公司赛诺菲 Genzyme担任高级医学总监。莫兰博士目前是上市生物制药公司BioAtla，Inc.的董事会成员。莫兰博士是一名获得董事会认证的内科医生，曾在宾夕法尼亚大学医学院和哈佛医学院担任教职。莫兰博士在弗吉尼亚大学获得化学学士学位，在杜克大学获得医学博士学位，在宾夕法尼亚大学医学院获得临床流行病学硕士学位。
Susan Moran has over 20 years of industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Dr. Moran has served on the board of directors of Tyra Biosciences, Inc. (Nasdaq: TYRA) since May 2024 and Crescent Biopharma since November 2024. From July 2021 to May 2024, Dr. Moran served as Chief Medical Officer of RayzeBio, Inc., a radiopharmaceutical therapeutics company previously listed on Nasdaq that was acquired by Bristol Myers Squibb in February 2024. Prior to joining RayzeBio, Dr. Moran served as Chief Medical Officer at QED Therapeutics, Inc., a biotechnology company and subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from March 2018 to June 2021, where she oversaw clinical development of infigratinib, leading to approval of TruseltiqTM. Prior to QED, Dr. Moran was at Puma Biotechnology, Inc. from 2014 to February 2018, contributing to the approval of Nerylnx. She was Senior Medical Director until December 2016 when her role expanded to Vice President and Head of Clinical Development. Dr. Moran has played roles in the development, registration, and post marketing support of products for breast, prostate, thyroid, bile duct, urothelial, lung, and neuroendocrine cancer, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine. - Susan Moran，自2021年7月起担任Rayzebio，Inc.首席医疗官。此前，莫兰博士曾于2018年3月至2021年6月担任上市生物技术公司BridgeBio Pharma的附属公司QED治疗公司的首席医疗官。在加入QED之前，莫兰博士于2014年至2018年2月在上市生物制药公司Puma Biotechnology, Inc.工作。莫兰博士一直担任高级医学主任，直到2016年12月，她的职位扩大到副总裁兼临床开发主管。在加入彪马之前，莫兰博士曾于2011年至2014年在上市生物制药公司Takeda Oncology担任医学总监，并于2007年至2011年在上市生物技术公司赛诺菲 Genzyme担任高级医学总监。莫兰博士目前是上市生物制药公司BioAtla，Inc.的董事会成员。莫兰博士是一名获得董事会认证的内科医生，曾在宾夕法尼亚大学医学院和哈佛医学院担任教职。莫兰博士在弗吉尼亚大学获得化学学士学位，在杜克大学获得医学博士学位，在宾夕法尼亚大学医学院获得临床流行病学硕士学位。
- Susan Moran has over 20 years of industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Dr. Moran has served on the board of directors of Tyra Biosciences, Inc. (Nasdaq: TYRA) since May 2024 and Crescent Biopharma since November 2024. From July 2021 to May 2024, Dr. Moran served as Chief Medical Officer of RayzeBio, Inc., a radiopharmaceutical therapeutics company previously listed on Nasdaq that was acquired by Bristol Myers Squibb in February 2024. Prior to joining RayzeBio, Dr. Moran served as Chief Medical Officer at QED Therapeutics, Inc., a biotechnology company and subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from March 2018 to June 2021, where she oversaw clinical development of infigratinib, leading to approval of TruseltiqTM. Prior to QED, Dr. Moran was at Puma Biotechnology, Inc. from 2014 to February 2018, contributing to the approval of Nerylnx. She was Senior Medical Director until December 2016 when her role expanded to Vice President and Head of Clinical Development. Dr. Moran has played roles in the development, registration, and post marketing support of products for breast, prostate, thyroid, bile duct, urothelial, lung, and neuroendocrine cancer, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine.
- S. Michael Rothenberg
-
S. Michael Rothenberg，自2024年5月起担任Tyra Biosciences, Inc.董事会成员。Rothenberg博士自2024年2月起担任insitro，Inc.的首席医疗官。在此之前，他曾于2020年3月至2024年1月在辉瑞任职，包括副总裁兼早期肿瘤学开发和临床研究负责人以及早期临床开发负责人。在任职于辉瑞之前，Rothenberg博士曾于2015年8月至2020年1月在Loxo Oncology公司担任多个职务，包括担任研发副总裁和研发总监。在从事生物技术工作之前，他是麻省总医院癌症中心的医学肿瘤学家和癌症研究人员。Rothenberg博士在耶鲁大学获得化学学士学位，并在斯坦福大学获得医学博士和博士学位。
S. Michael Rothenberg,has served as a member of Tyra Biosciences, Inc. Board since May 2024. Dr. Rothenberg has served as Chief Medical Officer of insitro, inc. since February 2024. Prior to this, he held positions at Pfizer from March 2020 to January 2024, including Vice President and Head of Early Oncology Development and Clinical Research and Head of Early Clinical Development. Before his time at Pfizer, Dr. Rothenberg served in various roles at Loxo Oncology, Inc. from August 2015 to January 2020, including as Vice President of Research and Development and as Director of Research and Development. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher at the Massachusetts General Hospital Cancer Center. Dr. Rothenberg received his B.A. in Chemistry from Yale University and earned his M.D. and Ph.D. from Stanford University. - S. Michael Rothenberg，自2024年5月起担任Tyra Biosciences, Inc.董事会成员。Rothenberg博士自2024年2月起担任insitro，Inc.的首席医疗官。在此之前，他曾于2020年3月至2024年1月在辉瑞任职，包括副总裁兼早期肿瘤学开发和临床研究负责人以及早期临床开发负责人。在任职于辉瑞之前，Rothenberg博士曾于2015年8月至2020年1月在Loxo Oncology公司担任多个职务，包括担任研发副总裁和研发总监。在从事生物技术工作之前，他是麻省总医院癌症中心的医学肿瘤学家和癌症研究人员。Rothenberg博士在耶鲁大学获得化学学士学位，并在斯坦福大学获得医学博士和博士学位。
- S. Michael Rothenberg,has served as a member of Tyra Biosciences, Inc. Board since May 2024. Dr. Rothenberg has served as Chief Medical Officer of insitro, inc. since February 2024. Prior to this, he held positions at Pfizer from March 2020 to January 2024, including Vice President and Head of Early Oncology Development and Clinical Research and Head of Early Clinical Development. Before his time at Pfizer, Dr. Rothenberg served in various roles at Loxo Oncology, Inc. from August 2015 to January 2020, including as Vice President of Research and Development and as Director of Research and Development. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher at the Massachusetts General Hospital Cancer Center. Dr. Rothenberg received his B.A. in Chemistry from Yale University and earned his M.D. and Ph.D. from Stanford University.
高管简历
中英对照 | 中文 | 英文- Todd Harris
Todd Harris自2018年11月以来担任我们的总裁，首席执行官和秘书，自2019年2月以来担任我们的财务主管，自2018年8月以来担任我们的董事会成员。在共同创立Tyra之前，Harris博士担任过各种职务，最近担任SiennaBiopharmaceuticals，Inc.的企业发展主管和董事。SNNA，即Sienna，一家临床阶段的生物制药公司，从2016年1月到2018年7月，此前从2013年4月到2016年1月担任Sienna（当时称为Sienna Labs）的创始人、首席执行官和董事。2019年9月，Sienna Biopharmaceuticals根据美国破产法第11章提出自愿申请，允许重组，并于2019年12月停止运营。在Sienna之前，从2008年9月到2012年12月，Harris博士是麦肯锡公司（McKinsey&Company）医疗实践部门的顾问。Harris博士目前是Primune Therapeutics，Inc.的董事会成员，该公司是一家生物制药公司，专注于第二只手——先天免疫系统。Harris博士拥有杨百翰大学电气工程理学学士学位，加州大学圣地亚哥分校生物工程理学硕士学位，麻省理工学院医学工程和医学物理学博士学位。
Todd Harris has served as our President, Chief Executive Officer and Secretary since November 2018 as our Treasurer since February 2019 and as a member of our board of directors since August 2018. Prior to co-founding Tyra, Dr. Harris served in various roles, most recently as Head of Corporate Development and a director at Sienna Biopharmaceuticals, Inc. SNNA, or Sienna, a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and previously as the founder, Chief Executive Officer, and director of Sienna (then called Sienna Labs) from April 2013 to January 2016. In September 2019 Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division from September 2008 to December 2012. Dr. Harris currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Dr. Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.- Todd Harris自2018年11月以来担任我们的总裁，首席执行官和秘书，自2019年2月以来担任我们的财务主管，自2018年8月以来担任我们的董事会成员。在共同创立Tyra之前，Harris博士担任过各种职务，最近担任SiennaBiopharmaceuticals，Inc.的企业发展主管和董事。SNNA，即Sienna，一家临床阶段的生物制药公司，从2016年1月到2018年7月，此前从2013年4月到2016年1月担任Sienna（当时称为Sienna Labs）的创始人、首席执行官和董事。2019年9月，Sienna Biopharmaceuticals根据美国破产法第11章提出自愿申请，允许重组，并于2019年12月停止运营。在Sienna之前，从2008年9月到2012年12月，Harris博士是麦肯锡公司（McKinsey&Company）医疗实践部门的顾问。Harris博士目前是Primune Therapeutics，Inc.的董事会成员，该公司是一家生物制药公司，专注于第二只手——先天免疫系统。Harris博士拥有杨百翰大学电气工程理学学士学位，加州大学圣地亚哥分校生物工程理学硕士学位，麻省理工学院医学工程和医学物理学博士学位。
- Todd Harris has served as our President, Chief Executive Officer and Secretary since November 2018 as our Treasurer since February 2019 and as a member of our board of directors since August 2018. Prior to co-founding Tyra, Dr. Harris served in various roles, most recently as Head of Corporate Development and a director at Sienna Biopharmaceuticals, Inc. SNNA, or Sienna, a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and previously as the founder, Chief Executive Officer, and director of Sienna (then called Sienna Labs) from April 2013 to January 2016. In September 2019 Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division from September 2008 to December 2012. Dr. Harris currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Dr. Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.
- Douglas Warner
Douglas Warner，自2022年8月起担任eFFECTOR Therapeutics, Inc.首席医疗官。在此之前，沃纳博士在安进工作了18年，在那里他负责肿瘤和普通医学的多个适应症的广泛临床开发项目。在最近的职位上，华纳博士担任集团产品领域主管，执行医疗总监，负责为广泛的实体瘤免疫肿瘤学和通路抑制剂开发项目提供开发指导和监督，这些项目的范围从1期到上市产品。在担任这一职务之前，华纳博士是Vectibix 、XGEVA 和Prolia 等多个产品的全球开发主管。在担任这一职务期间，华纳博士领导了证据的生成，并监督了研究在各个开发阶段的设计、执行和分析，包括大型全球3期试验，并且是全球主要监管文件的临床开发领导者。华纳博士是众多同行评议文章的合著者，包括《柳叶刀》、《柳叶刀肿瘤学》和《临床肿瘤学杂志》上的文章。他在宾夕法尼亚大学获得了学士学位，在杜克大学医学院获得了医学博士学位，在加州大学洛杉矶分校安德森管理学院获得了工商管理硕士学位。
Douglas Warner,has served as Effector Therapeutics, Inc. Chief Medical Officer since August 2022. Previously, Dr. Warner held roles of increasing responsibility over 18 years at Amgen where he oversaw extensive clinical development programs in multiple indications across oncology and general medicine. In his most recent position, Executive Medical Director, Group Product Area Lead, Dr. Warner provided development guidance and oversight over a broad portfolio of solid tumor immune-oncology and pathway inhibitor development programs that ranged from Phase 1 to marketed products. Prior to this position, Dr. Warner was the Global Development Lead for several products including Vectibix, XGEVA, and Prolia. In this role, Dr. Warner led evidence generation and oversaw the design, execution, and analysis of studies across the phases of development, including large global Phase 3 trials, and was the clinical development leader for major regulatory filings worldwide. Dr. Warner is co-author on numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology, and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine, and his M.B.A. from the UCLA Anderson School of Management.- Douglas Warner，自2022年8月起担任eFFECTOR Therapeutics, Inc.首席医疗官。在此之前，沃纳博士在安进工作了18年，在那里他负责肿瘤和普通医学的多个适应症的广泛临床开发项目。在最近的职位上，华纳博士担任集团产品领域主管，执行医疗总监，负责为广泛的实体瘤免疫肿瘤学和通路抑制剂开发项目提供开发指导和监督，这些项目的范围从1期到上市产品。在担任这一职务之前，华纳博士是Vectibix 、XGEVA 和Prolia 等多个产品的全球开发主管。在担任这一职务期间，华纳博士领导了证据的生成，并监督了研究在各个开发阶段的设计、执行和分析，包括大型全球3期试验，并且是全球主要监管文件的临床开发领导者。华纳博士是众多同行评议文章的合著者，包括《柳叶刀》、《柳叶刀肿瘤学》和《临床肿瘤学杂志》上的文章。他在宾夕法尼亚大学获得了学士学位，在杜克大学医学院获得了医学博士学位，在加州大学洛杉矶分校安德森管理学院获得了工商管理硕士学位。
- Douglas Warner,has served as Effector Therapeutics, Inc. Chief Medical Officer since August 2022. Previously, Dr. Warner held roles of increasing responsibility over 18 years at Amgen where he oversaw extensive clinical development programs in multiple indications across oncology and general medicine. In his most recent position, Executive Medical Director, Group Product Area Lead, Dr. Warner provided development guidance and oversight over a broad portfolio of solid tumor immune-oncology and pathway inhibitor development programs that ranged from Phase 1 to marketed products. Prior to this position, Dr. Warner was the Global Development Lead for several products including Vectibix, XGEVA, and Prolia. In this role, Dr. Warner led evidence generation and oversaw the design, execution, and analysis of studies across the phases of development, including large global Phase 3 trials, and was the clinical development leader for major regulatory filings worldwide. Dr. Warner is co-author on numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology, and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine, and his M.B.A. from the UCLA Anderson School of Management.
- Bhavesh Ashar
Bhavesh Ashar，此前于2021年3月至2025年9月期间担任SpringWorks Therapeutics，Inc.的首席商务官，此前该公司于2025年7月被默沙东 KGaA收购。2017年5月至2021年3月，Ashar先生担任拜耳高级副总裁兼美国肿瘤学总经理。在此之前，Ashar先生于2014年5月至2017年4月担任赛诺菲 Genzyme的副总裁兼美国肿瘤学总经理，并于2011年12月至2014年4月担任副总裁兼移植（肿瘤事业部）全球负责人，在更早之前，他曾在赛诺菲 Genzyme担任各种职务，任期约15年。Ashar先生在伦敦帝国理工学院获得数学理学学士学位，并在芝加哥大学布斯商学院获得MBA学位。
Bhavesh Ashar,previously served as Chief Commercial Officer of SpringWorks Therapeutics, Inc. from March 2021 until September 2025, following its acquisition by Merck KGaA in July 2025. From May 2017 to March 2021, Mr. Ashar served as Senior Vice President, General Manager of U.S. Oncology for Bayer. Prior to that, Mr. Ashar served as Vice President, General Manager of U.S. Oncology for Sanofi Genzyme from May 2014 to April 2017 and as Vice President, Global Head of Transplant (Oncology Division) from December 2011 to April 2014, and earlier, held various roles of increasing responsibility at Sanofi Genzyme over an approximately 15-year tenure. Mr. Ashar received a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.- Bhavesh Ashar，此前于2021年3月至2025年9月期间担任SpringWorks Therapeutics，Inc.的首席商务官，此前该公司于2025年7月被默沙东 KGaA收购。2017年5月至2021年3月，Ashar先生担任拜耳高级副总裁兼美国肿瘤学总经理。在此之前，Ashar先生于2014年5月至2017年4月担任赛诺菲 Genzyme的副总裁兼美国肿瘤学总经理，并于2011年12月至2014年4月担任副总裁兼移植（肿瘤事业部）全球负责人，在更早之前，他曾在赛诺菲 Genzyme担任各种职务，任期约15年。Ashar先生在伦敦帝国理工学院获得数学理学学士学位，并在芝加哥大学布斯商学院获得MBA学位。
- Bhavesh Ashar,previously served as Chief Commercial Officer of SpringWorks Therapeutics, Inc. from March 2021 until September 2025, following its acquisition by Merck KGaA in July 2025. From May 2017 to March 2021, Mr. Ashar served as Senior Vice President, General Manager of U.S. Oncology for Bayer. Prior to that, Mr. Ashar served as Vice President, General Manager of U.S. Oncology for Sanofi Genzyme from May 2014 to April 2017 and as Vice President, Global Head of Transplant (Oncology Division) from December 2011 to April 2014, and earlier, held various roles of increasing responsibility at Sanofi Genzyme over an approximately 15-year tenure. Mr. Ashar received a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.
- Alan Fuhrman
Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University.- Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
- Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University.